➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Colorcon
Johnson and Johnson
Mallinckrodt
Baxter

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

OLUMIANT Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Olumiant patents expire, and when can generic versions of Olumiant launch?

Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-four patent family members in forty-two countries.

The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.

DrugPatentWatch® Generic Entry Outlook for Olumiant

Olumiant will be eligible for patent challenges on May 31, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try Before You Buy

Summary for OLUMIANT
International Patents:54
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 94
Clinical Trials: 6
Patent Applications: 936
Drug Prices: Drug price information for OLUMIANT
What excipients (inactive ingredients) are in OLUMIANT?OLUMIANT excipients list
DailyMed Link:OLUMIANT at DailyMed
Drug patent expirations by year for OLUMIANT
Drug Prices for OLUMIANT

See drug prices for OLUMIANT

DrugPatentWatch® Estimated Generic Entry Opportunity Date for OLUMIANT
Generic Entry Date for OLUMIANT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OLUMIANT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Institut National de la Santé Et de la Recherche Médicale, FrancePhase 2/Phase 3
Oslo University HospitalPhase 2/Phase 3
Epidemiological and Clinical Research Information NetworkPhase 2/Phase 3

See all OLUMIANT clinical trials

Pharmacology for OLUMIANT

US Patents and Regulatory Information for OLUMIANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-002 Oct 8, 2019 RX Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Try Before You Buy   Try Before You Buy Y Y   Try Before You Buy
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-002 Oct 8, 2019 RX Yes No   Try Before You Buy   Try Before You Buy Y Y   Try Before You Buy
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for OLUMIANT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2288610 17C0005 France   Try Before You Buy PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170215
2288610 132017000078559 Italy   Try Before You Buy PRODUCT NAME: BARICITINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(OLUMIANT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1170, 20170215
2288610 LUC00027 Luxembourg   Try Before You Buy PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610 CA 2017 00032 Denmark   Try Before You Buy PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
Baxter
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.